India COVID-19 Update: Antivirals, Eyes On HCQ-Azithromycin Data
Cipla Among Firms Prepping Favipiravir, Remdesivir, Baloxavir Generics
Executive Summary
Development work for antivirals such as favipiravir and remdesivir seen as potential treatments for coronavirus is underway in India, with the former’s off-patent status making it more attractive. All eyes are also on data from a French study which highlights the potential of hydroxychloroquine and azithromycin as a COVID-19 treatment.
You may also be interested in...
Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK
Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares.
Gilead Looks To Collaborate On Remdesivir
Gilead has opened up discussions with potential licensing partners, including leading Indian firms, to rapidly scale up supplies of remdesivir, the antiviral that has received FDA emergency use authorization to tackle COVID-19. Healthcare activists say past licensing models used by the US firm are flawed and unacceptable during a global health emergency.